Takeda to Spend $1.7 Billion Next Three Years Buying Drugs From Others
This article was originally published in PharmAsia News
Executive SummaryTakeda Pharmaceutical plans to spend about $1.7 billion over the next three years to buy new products from other companies. That amount is in addition to normal expenditures Takeda sets aside annually to purchase drugs made by others. (Click here for more
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.